Adolfo G Favaretto

Summary

Country: Italy

Publications

  1. ncbi Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study
    Adolfo G Favaretto
    Department of Medical Oncology, University Hospital, Padova, Italy
    Cancer 97:2791-7. 2003
  2. ncbi Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease
    Savina M L Aversa
    Medical Oncology Department, University Hospital, Padova, Italy
    Acta Haematol 112:141-7. 2004
  3. ncbi Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
    J Clin Oncol 24:1443-8. 2006

Collaborators

Detail Information

Publications3

  1. ncbi Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study
    Adolfo G Favaretto
    Department of Medical Oncology, University Hospital, Padova, Italy
    Cancer 97:2791-7. 2003
    ..Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated...
  2. ncbi Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease
    Savina M L Aversa
    Medical Oncology Department, University Hospital, Padova, Italy
    Acta Haematol 112:141-7. 2004
    ..Longer follow-up is necessary to evaluate the extent of all complications...
  3. ncbi Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
    J Clin Oncol 24:1443-8. 2006
    ..This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM)...